581 related articles for article (PubMed ID: 33435306)
1. The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression.
García-Ortiz A; Rodríguez-García Y; Encinas J; Maroto-Martín E; Castellano E; Teixidó J; Martínez-López J
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435306
[TBL] [Abstract][Full Text] [Related]
2. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
3. Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.
Calcinotto A; Ponzoni M; Ria R; Grioni M; Cattaneo E; Villa I; Sabrina Bertilaccio MT; Chesi M; Rubinacci A; Tonon G; Bergsagel PL; Vacca A; Bellone M
Oncoimmunology; 2015 Jun; 4(6):e1008850. PubMed ID: 26155424
[TBL] [Abstract][Full Text] [Related]
4. High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments.
Fernandez N; Perumal D; Rahman A; Kim-Schulze S; Yesil J; Auclair D; Adams H; Parekh S; Gnjatic S; Cho HJ
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):853-862. PubMed ID: 35945129
[TBL] [Abstract][Full Text] [Related]
5. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.
Plano F; Corsale AM; Gigliotta E; Camarda G; Vullo C; Di Simone M; Shekarkar Azgomi M; Speciale M; Carlisi M; Caccamo N; Dieli F; Meraviglia S; Siragusa S; Botta C
Hematol Rep; 2023 Jan; 15(1):23-49. PubMed ID: 36648882
[TBL] [Abstract][Full Text] [Related]
7. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ;
Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
9. Targeting the bone marrow microenvironment in multiple myeloma.
Kawano Y; Moschetta M; Manier S; Glavey S; Görgün GT; Roccaro AM; Anderson KC; Ghobrial IM
Immunol Rev; 2015 Jan; 263(1):160-72. PubMed ID: 25510276
[TBL] [Abstract][Full Text] [Related]
10. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
11. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
[TBL] [Abstract][Full Text] [Related]
13. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
14. Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease.
Forster S; Radpour R
Front Oncol; 2022; 12():941437. PubMed ID: 35847862
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow microenvironment in multiple myeloma progression.
Manier S; Sacco A; Leleu X; Ghobrial IM; Roccaro AM
J Biomed Biotechnol; 2012; 2012():157496. PubMed ID: 23093834
[TBL] [Abstract][Full Text] [Related]
16. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
17. Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.
Damasceno D; Almeida J; Teodosio C; Sanoja-Flores L; Mayado A; Pérez-Pons A; Puig N; Arana P; Paiva B; Solano F; Romero A; Matarraz S; van den Bossche WBL; Flores-Montero J; Durie B; van Dongen JJM; Orfao A
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810169
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities.
Botta C; Mendicino F; Martino EA; Vigna E; Ronchetti D; Correale P; Morabito F; Neri A; Gentile M
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34203150
[TBL] [Abstract][Full Text] [Related]
19. Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia.
Janker L; Mayer RL; Bileck A; Kreutz D; Mader JC; Utpatel K; Heudobler D; Agis H; Gerner C; Slany A
Mol Cell Proteomics; 2019 May; 18(5):936-953. PubMed ID: 30792264
[TBL] [Abstract][Full Text] [Related]
20. The immune microenvironment of myeloma.
Noonan K; Borrello I
Cancer Microenviron; 2011 Dec; 4(3):313-23. PubMed ID: 21866321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
